BG101607A - Dihydropyrimdines and uses thereof - Google Patents

Dihydropyrimdines and uses thereof

Info

Publication number: BG101607A
Authority: BG; Bulgaria
Prior art keywords: relates; compounds; impotence; antagonism; relaxing
Prior art date: 1994-11-16

Application number

BG101607A

Other languages

Bulgarian (bg)

English (en)

Inventor

Dhanapalan Nagarathnam

George Chiu

Murali Dhar

Wai Wong

Mohammad Marzabadi

Charles Gluchowski

Shou Miao

Bharat Ladu

Original Assignee

Synaptic Pharmaceutical Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-16

Filing date

1997-06-12

Publication date

1998-02-27

1997-06-12 Application filed by Synaptic Pharmaceutical Corporation filed Critical Synaptic Pharmaceutical Corporation

1998-02-27 Publication of BG101607A publication Critical patent/BG101607A/xx

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical class C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 abstract 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
230000008485 antagonism Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
206010003119 arrhythmia Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
208000019622 heart disease Diseases 0.000 abstract 1
201000001881 impotence Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000004410 intraocular pressure Effects 0.000 abstract 1
230000002040 relaxant effect Effects 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000002485 urinary effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)

BG101607A 1994-11-16 1997-06-12 Dihydropyrimdines and uses thereof BG101607A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34061194A	1994-11-16	1994-11-16
PCT/US1995/015025 WO1996014846A1 (en)	1994-11-16	1995-11-16	Dihydropyrimidines and uses thereof

Publications (1)

Publication Number	Publication Date
BG101607A true BG101607A (en)	1998-02-27

Family

ID=23334169

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG101607A BG101607A (en)	1994-11-16	1997-06-12	Dihydropyrimdines and uses thereof

Country Status (24)

Country	Link
US (2)	US5942517A (is)
EP (1)	EP0790826A4 (is)
JP (1)	JP3200070B2 (is)
KR (1)	KR970706823A (is)
CN (1)	CN1173132A (is)
AR (1)	AR005238A1 (is)
AU (1)	AU714640B2 (is)
BG (1)	BG101607A (is)
BR (1)	BR9509700A (is)
CA (1)	CA2205384C (is)
CO (1)	CO4950529A1 (is)
CZ (1)	CZ151297A3 (is)
EE (1)	EE9700209A (is)
FI (1)	FI972087L (is)
HU (1)	HUT77941A (is)
IS (1)	IS4481A (is)
MD (1)	MD970227A (is)
MX (1)	MX9703518A (is)
NO (1)	NO972236L (is)
NZ (1)	NZ297278A (is)
PL (1)	PL320263A1 (is)
SK (1)	SK60097A3 (is)
WO (1)	WO1996014846A1 (is)
YU (1)	YU60696A (is)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0790826A4 (en)	1994-11-16	1998-11-11	Synaptic Pharma Corp	DIHYDROPYRIMIDINES AND THEIR USES
US6268369B1 (en)	1994-11-16	2001-07-31	Synaptic Pharmaceutical Corporation	5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US5661163A (en) *	1995-06-07	1997-08-26	Merck & Co., Inc.	Alpha-1a adrenergic receptor antagonists
US6228861B1 (en)	1995-11-16	2001-05-08	Synaptic Pharmaceutical Corporation	Dihydropyrimidines and uses thereof
US6245773B1 (en)	1996-05-16	2001-06-12	Synaptic Pharmaceutical Corporation	5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EP1021185A4 (en) *	1996-05-16	2005-09-07	Synaptic Pharma Corp	DIHYDROPYRIMIDINES AND THEIR JOBS
US6172066B1 (en)	1996-05-16	2001-01-09	Synaptic Pharmaceutical Corporation	Dihydropyrimidines and uses thereof
US6057350A (en) *	1997-06-18	2000-05-02	Merck & Co., Inc.	Alpha 1a adrenergic receptor antagonists
US6080760A (en) *	1997-06-18	2000-06-27	Merck & Co., Inc.	Alpha 1A adrenergic receptor antagonists
AU740064B2 (en) *	1997-06-18	2001-10-25	H. Lundbeck A/S	Heterocyclic substituted piperidines and uses thereof
US6376503B1 (en)	1997-06-18	2002-04-23	Merck & Co., Inc	Alpha 1a adrenergic receptor antagonists
US6214832B1 (en)	1997-06-18	2001-04-10	Merck & Co., Inc.	Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
WO1998057641A1 (en) *	1997-06-18	1998-12-23	Merck & Co., Inc.	ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
US6143750A (en) *	1997-06-18	2000-11-07	Merck & Co., Inc.	Alpha 1a adrenergic receptor antagonists
US6037354A (en) *	1997-06-18	2000-03-14	Merck & Co., Inc.	Alpha 1a adrenergic receptor antagonists
US6271234B1 (en)	1997-08-01	2001-08-07	Recordati S.A., Chemical And Pharmaceutical Company	1,4-disubstituted piperazines
WO1999007695A2 (en) *	1997-08-05	1999-02-18	Merck & Co., Inc.	ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST
US6207444B1 (en)	1997-08-05	2001-03-27	Merck & Co., Inc.	Enzymatic process of making alpha 1a adrenergic receptor antagonists using protease
US6410554B1 (en)	1998-03-23	2002-06-25	Merck & Co., Inc.	Combination therapy for the treatment of benign prostatic hyperplasia
AU3011299A (en) *	1998-03-23	1999-10-18	Merck & Co., Inc.	Combination therapy for the treatment of benign prostatic hyperplasia
AU5234899A (en) *	1998-07-30	2000-02-21	Merck & Co., Inc.	Alpha 1a adrenergic receptor antagonists
US6268377B1 (en)	1998-09-28	2001-07-31	Merck & Co., Inc.	Method for treating androgen-related conditions
WO2000025782A1 (en)	1998-10-29	2000-05-11	Merck & Co., Inc.	Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en)	1998-11-10	2001-11-20	Merck & Co., Inc.	Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6228870B1 (en)	1998-11-10	2001-05-08	Merck & Co., Inc.	Oxazolidinones useful as alpha 1a adrenoceptor antagonists
AU1345600A (en) *	1998-11-12	2000-06-05	Merck & Co., Inc.	Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
GB2344821A (en)	1998-12-17	2000-06-21	Merck & Co Inc	Crystalline pharmaceutically acceptable salt of an oxazolidinone derivative
US6680323B2 (en)	1998-12-23	2004-01-20	Synaptic Pharmaceutical Corporation	Dihydropyrimidines and uses thereof
JP2002532525A (ja) *	1998-12-23	2002-10-02	シナプティック・ファーマスーティカル・コーポレーション	ジヒドロピリミジンおよびその使用
US6274585B1 (en) *	1998-12-23	2001-08-14	Synaptic Pharmaceutical Corporation	Dihydropyrimidines and uses thereof
GB2346142A (en) *	1999-01-26	2000-08-02	Merck & Co Inc	Pyrimidinones useful for treating benign prostatic hyperplasia
WO2000078730A1 (en)	1999-06-23	2000-12-28	Ajinomoto Co., Inc.	Novel dihydropyrimidine derivatives
GB2355456A (en)	1999-09-30	2001-04-25	Merck & Co Inc	Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en)	1999-09-30	2001-04-18	Merck & Co Inc	Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en)	1999-09-30	2001-04-18	Merck & Co Inc	Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en)	1999-09-30	2001-04-25	Merck & Co Inc	Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
US6720324B2 (en)	2000-07-05	2004-04-13	Synaptic Pharmaceutical Corporation	Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
EP1299362A4 (en) *	2000-07-05	2004-11-03	Synaptic Pharma Corp	SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
US6900214B2 (en)	2001-03-29	2005-05-31	Bristol-Myers Squibb Company	Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en)	2001-03-29	2004-10-26	Bristol-Myers Squibb Company	Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
IL159741A0 (en)	2001-07-13	2004-06-20	Astrazeneca Uk Ltd	Preparation of aminopyrimidine compounds
ES2335279T3 (es)	2002-12-16	2010-03-24	Astrazeneca Uk Limited	Procedimiento para la preparacion de compuestos de pirimidina.
WO2005007124A2 (en)	2003-07-23	2005-01-27	Bristol-Myers Squibb Company	Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en)	2003-07-23	2007-01-23	Bristol-Myers Squibb Co.	Dihydropyrimidone inhibitors of calcium channel function
CA2552087C (en) *	2004-01-30	2011-01-25	Euro-Celtique S.A.	Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
GB0428328D0 (en)	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
WO2007101213A2 (en) *	2006-02-28	2007-09-07	Kalypsys, Inc.	Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
CL2007002958A1 (es) *	2006-10-12	2008-05-09	Epix Delaware Inc	Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
WO2009076512A1 (en)	2007-12-11	2009-06-18	Epix Delaware, Inc.	Carboxamidξ compounds and their use as chemokine receptor agonists
MD20140044A2 (ro)	2011-11-11	2014-08-31	Pfizer Inc.	2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
AU2016257179A1 (en)	2015-05-05	2017-11-02	Pfizer Inc.	2-thiopyrimidinones
US20160361380A1 (en)	2015-06-12	2016-12-15	Nymox Corporation	Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5659778A (en)	1979-10-23	1981-05-23	Showa Denko Kk	Dimethylthienopyrimidione derivative
US4438117A (en)	1980-09-03	1984-03-20	E. I. Du Pont De Nemours And Company	2-Substituted thio-4,5-diarylpyrimidines
US4683234A (en)	1984-05-19	1987-07-28	Suntory Limited	2,6-Dimethyl-3N,5-disubstituted-4-(substituted phenyl)3,4-dihydropyrimidine compounds and a method for treating disorders of cardiocircular system
US4684653A (en) *	1985-03-08	1987-08-04	The Trustees Of Princeton University	Pyrido(2,3-d)pyrimidine derivatives
US4728652A (en)	1985-05-20	1988-03-01	E. R. Squibb & Sons, Inc.	2-substituted thio or oxy-4-aryl or heterocyclo-5-carboxy-1,4-dihydropyrimidines, composition containing them, and method of using them to reduce blood pressure
US5202330A (en) *	1985-06-03	1993-04-13	E. R. Squibb & Sons, Inc.	2-thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid diesters and 3-acyl-5-pyrimidinecarboxylic acids and esters
HUT42077A (en)	1985-06-03	1987-06-29	Squibb & Sons Inc	Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters
JPS6287574A (ja)	1985-10-14	1987-04-22	Suntory Ltd	新規なｎ置換３，４−ジヒドロピリミジン−２−オン誘導体、その製造法及び循環器系疾患治療剤
US4689414A (en) *	1986-02-24	1987-08-25	E. R. Squibb & Sons, Inc.	2-(substituted imino)-6-aryl-3,6-dihydro-4-substituted-1,5(2H)-pyrimidinecarboxylic acids and analogs
US4855301A (en) *	1986-10-09	1989-08-08	E. R. Squibb & Sons, Inc.	1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters
US4684656A (en)	1986-03-14	1987-08-04	E. R. Squibb & Sons, Inc.	1,2,3,4-tetrahydro-6-substituted-4-aryl-3-(substituted sulfonyl)-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters and method of using them to lower blood pressure
US4684655A (en)	1986-03-14	1987-08-04	E. R. Squibb & Sons, Inc.	1,2,3,4-tetrahydro-6-substituted-4-aryl-3-substituted-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters and use thereof to lower blood pressure
CA1275410C (en) *	1986-03-14	1990-10-23	Karnail S. Atwal	1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo) -3-substituted-2-thioxo(or oxo)-5- pyrimidinecarboxylic acids and esters
IL81800A0 (en)	1986-03-14	1987-10-20	Squibb & Sons Inc	1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo(or oxo)-5-pyrimidine-carboxylic acids and esters and pharmaceutical compositions containing the same
US4703120A (en)	1986-04-28	1987-10-27	Ortho Pharmaceutical Corporation	Furo(3,4-d)pyrimidine-2,4-dione derivatives and intermediates thereof
US4902796A (en) *	1986-10-20	1990-02-20	The Trustees Of Princeton University	6-alkenyl and ethynyl derivatives of 2-amino-4-hydroxypyrido[2,3-d]pyrimidines
FR2610625B1 (fr) *	1987-02-10	1989-06-30	Inst Organicheskogo Sinteza Ak	2-oxo-4-(2'-difluoromethylthiophenyl)5-methoxycarbonyl-6-methyl-1,2,3,4-tetrahydropyrimidine
JPS63208580A (ja)	1987-02-21	1988-08-30	Suntory Ltd	Ｎ置換３，４−ジヒドロピリミジン誘導体および循環器系疾患治療剤
JP2830008B2 (ja) *	1988-04-01	1998-12-02	武田薬品工業株式会社	縮合ピリミジン誘導体
US5149810A (en)	1988-04-22	1992-09-22	Imperial Chemical Industries Plc	Pyrimidine compounds
US4882334A (en) *	1988-05-25	1989-11-21	The Trustees Of Princeton University	N-(5,6,7,8-tetrahydropyrido]2,3-d]pyrimidin-6-ylethl-thineyl-and furylcarbonyl)-glutamic acid derivatives
GB8906168D0 (en)	1989-03-17	1989-05-04	Pfizer Ltd	Therapeutic agents
CA2016465A1 (en) *	1989-06-02	1990-12-02	Zola Phillip Horovitz	Method for preventing or treating anxiety employing a calcium channel blocker
EP0459568A3 (en)	1990-05-31	1992-09-30	Merck Sharp & Dohme Ltd.	Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
DK0459666T3 (da) *	1990-05-31	1994-12-05	Pfizer	Lægemidler mod impotens
US5166148A (en) *	1990-07-09	1992-11-24	The Du Pont Merck Pharmaceutical Company	2-amino-1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
JPH06507392A (ja) *	1991-02-26	1994-08-25	エイアールシー　１，インコーポレイテッド	交感神経性の持続性疼痛の治療のための組成物および方法
RU2086544C1 (ru)	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5403847A (en) *	1992-11-13	1995-04-04	Synaptic Pharmaceutical Corporation	Use of α1C specific compounds to treat benign prostatic hyperlasia
IL109220A0 (en) *	1993-04-05	1994-07-31	Synaptic Pharma Corp	Dihydropyridines and new uses thereof
DE4313690A1 (de) *	1993-04-27	1994-11-03	Bayer Ag	Kondensierte Chinolyl-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE4313692A1 (de) *	1993-04-27	1994-11-03	Bayer Ag	3-Chinolyl substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE4313693A1 (de) *	1993-04-27	1994-11-03	Bayer Ag	2-Amino-4-chinolin-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung
TW394761B (en)	1993-06-28	2000-06-21	Hoffmann La Roche	Novel Sulfonylamino Pyrimidines
NZ264063A (en)	1993-08-13	1995-11-27	Nihon Nohyaku Co Ltd	N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
US5521189A (en)	1994-05-06	1996-05-28	The University Of Nc At Ch	Methods of treating pneumocystis carinii pneumonia
EP0790826A4 (en)	1994-11-16	1998-11-11	Synaptic Pharma Corp	DIHYDROPYRIMIDINES AND THEIR USES
US5594141A (en)	1994-11-23	1997-01-14	Neurogen Corporation	Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
US6245773B1 (en)	1996-05-16	2001-06-12	Synaptic Pharmaceutical Corporation	5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EP1021185A4 (en)	1996-05-16	2005-09-07	Synaptic Pharma Corp	DIHYDROPYRIMIDINES AND THEIR JOBS
WO1999007695A2 (en)	1997-08-05	1999-02-18	Merck & Co., Inc.	ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST
AU3011299A (en)	1998-03-23	1999-10-18	Merck & Co., Inc.	Combination therapy for the treatment of benign prostatic hyperplasia

1995
- 1995-11-16 EP EP95940748A patent/EP0790826A4/en not_active Withdrawn
- 1995-11-16 JP JP51635496A patent/JP3200070B2/ja not_active Expired - Fee Related
- 1995-11-16 PL PL95320263A patent/PL320263A1/xx unknown
- 1995-11-16 WO PCT/US1995/015025 patent/WO1996014846A1/en not_active Ceased
- 1995-11-16 FI FI972087A patent/FI972087L/fi unknown
- 1995-11-16 BR BR9509700A patent/BR9509700A/pt not_active Application Discontinuation
- 1995-11-16 EE EE9700209A patent/EE9700209A/xx unknown
- 1995-11-16 CN CN95197348A patent/CN1173132A/zh active Pending
- 1995-11-16 MD MD97-0227A patent/MD970227A/ro unknown
- 1995-11-16 KR KR1019970703311A patent/KR970706823A/ko not_active Withdrawn
- 1995-11-16 NZ NZ297278A patent/NZ297278A/xx unknown
- 1995-11-16 SK SK600-97A patent/SK60097A3/sk unknown
- 1995-11-16 CA CA002205384A patent/CA2205384C/en not_active Expired - Fee Related
- 1995-11-16 MX MX9703518A patent/MX9703518A/es unknown
- 1995-11-16 CZ CZ971512A patent/CZ151297A3/cs unknown
- 1995-11-16 AU AU42398/96A patent/AU714640B2/en not_active Ceased
- 1995-11-16 HU HU9801222A patent/HUT77941A/hu unknown
1996
- 1996-11-15 YU YU60696A patent/YU60696A/sh unknown
- 1996-11-15 AR ARP960105207A patent/AR005238A1/es unknown
- 1996-11-15 CO CO96060341A patent/CO4950529A1/es unknown
1997
- 1997-05-12 IS IS4481A patent/IS4481A/is unknown
- 1997-05-15 NO NO972236A patent/NO972236L/no unknown
- 1997-06-12 BG BG101607A patent/BG101607A/xx unknown
- 1997-11-26 US US08/978,682 patent/US5942517A/en not_active Expired - Fee Related
1999
- 1999-04-14 US US09/291,553 patent/US6248747B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU4239896A (en)	1996-06-06
FI972087A7 (fi)	1997-07-14
NZ297278A (en)	1999-06-29
YU60696A (sh)	1998-12-23
KR970706823A (ko)	1997-12-01
BR9509700A (pt)	1998-11-03
EP0790826A1 (en)	1997-08-27
SK60097A3 (en)	1998-01-14
AR005238A1 (es)	1999-04-28
CA2205384A1 (en)	1996-05-23
MD970227A (ro)	1999-05-31
US5942517A (en)	1999-08-24
CZ151297A3 (cs)	1998-07-15
EP0790826A4 (en)	1998-11-11
IS4481A (is)	1997-05-12
FI972087L (fi)	1997-07-14
FI972087A0 (fi)	1997-05-15
WO1996014846A1 (en)	1996-05-23
CA2205384C (en)	2004-06-29
NO972236L (no)	1997-07-01
AU714640B2 (en)	2000-01-06
NO972236D0 (no)	1997-05-15
PL320263A1 (en)	1997-09-15
CO4950529A1 (es)	2000-09-01
JP3200070B2 (ja)	2001-08-20
HUT77941A (hu)	1998-12-28
MX9703518A (es)	1997-08-30
JPH10510247A (ja)	1998-10-06
EE9700209A (et)	1998-04-15
US6248747B1 (en)	2001-06-19
CN1173132A (zh)	1998-02-11

Publication	Publication Date	Title
BG101607A (en)	1998-02-27	Dihydropyrimdines and uses thereof
WO1998051311A3 (en)	1999-01-14	Dihydropyrimidines and uses thereof
EP1027011A4 (en)	2002-03-06	ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING
NO985975L (no)	1999-02-18	Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
Kirby et al.	1997	Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future
WO2000064441A3 (en)	2001-06-14	Compound for use as a medicament for treatment of disorders involving bronchocontraction
UA90077C2 (uk)	2010-04-12	Антидисритмічні агенти для лікування тазового болю, що призначаються вагінально
GB0005251D0 (en)	2000-04-26	Therapeutic compounds
HK1038755A1 (zh)	2002-03-28	Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
WO2002060392A3 (en)	2003-09-25	Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
CA2378613A1 (en)	2001-01-11	Selective iglur5 receptor antagonists for the treatment of migraine
AU2088597A (en)	1997-10-01	Antagonism of endothelin actions
EP1806135A3 (en)	2010-11-24	The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO1999029729A3 (en)	1999-07-15	Antagonists of neuropilin receptor function and use thereof
MX9603489A (es)	1997-03-29	Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos.
AU9245601A (en)	2002-04-08	Peptide-based compounds
PL316533A1 (en)	1997-01-20	Progesterone antagonists used for producing therapeutic agents useful in treating dysfunctional metrorrhagiae
SE0002754D0 (sv)	2000-07-21	New pharmaceutical combination formulation and method of treatment with the combination
FI963083A0 (fi)	1996-08-05	Normotensiivisen glaukooman hoito angiotensiini-II-antagonisteilla
IL132853A0 (en)	2001-03-19	Combination therapy for modulating the human sexual response
GEP20074132B (en)	2007-06-25	Use of adenosine receptor a1 antagonists for treatment of pulmonary disease
WO2001022919A3 (en)	2002-07-11	Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof
DK0750614T3 (da)	2001-09-10	Quinazolinyl-aminoderivater med alfa-antagonist-aktivitet
WO2001079209A3 (en)	2002-05-16	Diazafluorenone il-8 antagonists
PT1000046E (pt)	2004-04-30	Derivados de piperazina activos no trato urinario inferior